Abstract
At present, surgery is still the recommended principal treatment for breast cancer. However, there are conditions in which surgery is not suitable, for example in elderly or high-risk patients and those who do not wish to undergo the procedure. This study presents a case series of 8 patients with unresected breast cancer who were administered hormonal therapy as an optional treatment. Patients included in the study were diagnosed with Stage I - ID breast cancer from 2012 to 2015 at our institution. The patients were administered hormonal therapy for an average duration of 20.1 months. Complete responses were seen in 4 patients, while 1 and 3 patients were noted to have a partial response and stable disease, respectively. No disease progression was seen in any patients during the study period. Endocrine therapy may be an effective and safe option for patients with unresected breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1645-1647 |
| Number of pages | 3 |
| Journal | Japanese Journal of Cancer and Chemotherapy |
| Volume | 45 |
| Issue number | 11 |
| Publication status | Published - Nov 1 2018 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
Significance of endocrine therapy for unresected primary breast cancer. / Kurata, Kanako; Kai, Masaya; Kubo, Makoto; Mori, Hitomi; Yamada, Mai; Nakafusa, Yuji; Nakamura, Masafumi.
In: Japanese Journal of Cancer and Chemotherapy, Vol. 45, No. 11, 01.11.2018, p. 1645-1647.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Significance of endocrine therapy for unresected primary breast cancer
AU - Kurata, Kanako
AU - Kai, Masaya
AU - Kubo, Makoto
AU - Mori, Hitomi
AU - Yamada, Mai
AU - Nakafusa, Yuji
AU - Nakamura, Masafumi
PY - 2018/11/1
Y1 - 2018/11/1
N2 - At present, surgery is still the recommended principal treatment for breast cancer. However, there are conditions in which surgery is not suitable, for example in elderly or high-risk patients and those who do not wish to undergo the procedure. This study presents a case series of 8 patients with unresected breast cancer who were administered hormonal therapy as an optional treatment. Patients included in the study were diagnosed with Stage I - ID breast cancer from 2012 to 2015 at our institution. The patients were administered hormonal therapy for an average duration of 20.1 months. Complete responses were seen in 4 patients, while 1 and 3 patients were noted to have a partial response and stable disease, respectively. No disease progression was seen in any patients during the study period. Endocrine therapy may be an effective and safe option for patients with unresected breast cancer.
AB - At present, surgery is still the recommended principal treatment for breast cancer. However, there are conditions in which surgery is not suitable, for example in elderly or high-risk patients and those who do not wish to undergo the procedure. This study presents a case series of 8 patients with unresected breast cancer who were administered hormonal therapy as an optional treatment. Patients included in the study were diagnosed with Stage I - ID breast cancer from 2012 to 2015 at our institution. The patients were administered hormonal therapy for an average duration of 20.1 months. Complete responses were seen in 4 patients, while 1 and 3 patients were noted to have a partial response and stable disease, respectively. No disease progression was seen in any patients during the study period. Endocrine therapy may be an effective and safe option for patients with unresected breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=85056702074&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056702074&partnerID=8YFLogxK
M3 - Article
VL - 45
SP - 1645
EP - 1647
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
SN - 0385-0684
IS - 11
ER -